Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
growth), turned cash-flow positive in the quarter, and raised 2026 product revenue guidance to $480–$495 million while continuing to invest in commercialization and pipeline programs. Commercial positioning and expansion: ZORYVE holds roughly a 50% share of the advanced topical therapy market with about 85% commercial coverage and 80% of prescriptions paid (gross-to-net ~50%), and management plans to expand the sales force from 130 to 160 reps and bring primary-care promotion in-house alongside DTC marketing partnerships. Pipeline and label growth: The company expects pediatric label expansions (psoriasis approval for ages 2–5 in June and a planned filing to extend use down to 3 months), is running phase II trials in vitiligo and hidradenitis suppurativa with readouts due later this year and early next, and has initiated phase I testing of ARQ-234 for atopic dermatitis. Interested in Arcutis Biotherapeutics, Inc.? Here are five stocks we like better. 3 Biotech Catalysts Presen
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewswire
- Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? [Yahoo! Finance]Yahoo! Finance
- How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets [Yahoo! Finance]Yahoo! Finance
- Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Arcutis Biotherapeutics (ARQT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 3/26/26 - Form SCHEDULE
- ARQT's page on the SEC website